RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.
Salah-Eddin Al-Batran
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Lilly
Sang Cheul Oh
No relevant relationships to disclose
Gyorgy Bodoky
No relevant relationships to disclose
Yasuhiro Shimada
Honoraria - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
Shuichi Hironaka
No relevant relationships to disclose
Naotoshi Sugimoto
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Oleg N. Lipatov
No relevant relationships to disclose
Tae-You Kim
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Philippe Rougier
Consultant or Advisory Role - Lilly Lab France
Honoraria - Lilly Lab France
Kei Muro
No relevant relationships to disclose
Astra M. Liepa
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Shaila Ballal
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael Emig
Employment or Leadership Position - Lilly Deutschland GmbH
Stock Ownership - Lilly
Atsushi Ohtsu
No relevant relationships to disclose
Hansjochen Wilke
Honoraria - Lilly